Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab

British Journal of Ophthalmology

Volumn 98, Issue 2, 2014, Pages 179-181

  Muether, Philipp S ^a   Droege, Katharina M ^a   Fauser, Sascha ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; ENZYME REPRESSION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LIMIT OF DETECTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VERY ELDERLY; VISUAL ACUITY;

AQUEOUS HUMOUR; DRUGS; MACULA;

ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84892595109     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303954     Document Type: Article

References (9)

1. Roh MI, Kim HS, Song JH, et al. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 2009; 116: 80-6.
2. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2006; 113: 294-301. (Pubitemid 43170779)
3. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-25.
4. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801.
5. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) 2008; 22: 42-8.
6. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011; 152: 686-94.
7. Muether PS, Hermann MM, Viebahn U, et al. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology 2012; 119: 2082-6.
8. Muether PS, Hermann MM, Dröge K, et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol 2013; 156: 989-93.
9. Funk M, Schmidinger G, Maar N, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina 2010; 30: 1412-19.